Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China. It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, and psoriasis. The company also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial. In addition, its products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB016, a biosimilar product candidate of dupilumab for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), and prurigo nodularis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, the company is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs. Mabpharm Limited was incorporated in 2018 and is headquartered in Taizhou, China.
